Podlesak Dennis
SEC Form 4 insider trading activity
Podlesak Dennis has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Oct 30, 2026.
On the most recent filing, Podlesak Dennis is listed as Director at Syndax Pharmaceuticals Inc. Inside the rolling window, Podlesak Dennis reported no open-market purchases and 1 open-market sale totaling $114K in SNDX.
Companies traded
Other insiders at SNDX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$114K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Podlesak Dennis made?
Podlesak Dennis has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Podlesak Dennis trade?
Podlesak Dennis has filed SEC Form 4 disclosures for 1 company, including SNDX.
When was Podlesak Dennis's most recent SEC Form 4 filing?
Podlesak Dennis's most recent SEC Form 4 filing on Tracefour is dated Oct 30, 2026.
What is Podlesak Dennis's total buy and sell value in the current window?
Inside the rolling retention window, Podlesak Dennis bought $0 and sold $114K based on SEC Form 4 filings.
What was Podlesak Dennis's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 8,000 SNDX shares on 2026-10-29, worth $114K, per SEC Form 4 filings.